Exploration of Targeted Anti-tumor Therapy

Home
/
Exploration of Targeted Anti-tumor Therapy
/
Articles
/
T1

From: Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets

Table 1

Summary of studies, which demonstrated relationships between levels of MDSCs and tumorigenesis in CRC patients

Sample type	MDSC phenotype	Number of samples	Main findings	References
Peripheral blood	Lin^–/lowHLA-DR^– CD11b⁺CD33⁺ MDSCs	64 patients	Increased percentage and the absolute number of Lin^–/lowHLA-DR^–CD11b⁺CD33⁺ MDSCs compared with healthy controls. This increase is closely correlated with clinical cancer stage and tumor metastasis but not primary tumor size	[20]
Peripheral blood	CD11b⁺CD33⁺HLA-DR^– MDSCs	23 patients with stage IV metastatic CRC	Patients with advanced CRC display enhanced MDSC levels and reduced CD247 expression	[37]
Peripheral blood and tumor tissues	CD33⁺HLA-DR^– MDSC	49 CRC patients	A considerable increase in the percentage of CD33⁺HLA-DR^– MDSCs was observed in the peripheral blood and tumor tissues of CRC patients as compared with healthy controls	[18]
Peripheral blood and tumor tissues	CD33⁺CD11b⁺HLA-DR^–	32 age-matched healthy donors and 42 patients with CRC at the time of first diagnosis	CRC patients had elevated levels of CD33⁺CD11b⁺HLA-DR^– MDSCs in primary tumor tissues and in peripheral blood. These elevated circulating MDSCs were correlated with advanced TNM stages and lymph node metastases	[42]
Tumor tissues	CD45⁺Lin^–HLA-DR^– CD11b⁺CD33⁺CD66b⁺	154 patients with colorectal adenocarcinoma	Activated inflammatory-DCs induced γδT17 cells to secrete IL-8, tumor necrosis factor alpha, and GM-CSF with a concomitant accumulation of immunosuppressive PMN-MDSCs in the tumor	[44]
Tumor tissues	CD33⁺CD11b⁺HLA-DR^– MDSCs	145 newly diagnosed CRC patients who did not accept any preoperative chemoradiotherapy	A significant association between CD33⁺ MDSC number and YAP1 and PTEN levels in CRC patients. The CD33⁺ MDSCs, YAP1, and PTEN were identified as predictors for the prognosis of CRC patients	[46]
Peripheral blood and tumor tissues	CD33⁺CD11b⁺HLA-DR^–/lowCD15⁺CD33⁺CD11b⁺HLA- DR^–CD14^–CD15⁻	21 CRC and 21 healthy donors	The expansion of peripheral GMCs correlated with higher stage and histological grade of cancer, thereby suggesting their role in cancer progression	[47]
Peripheral blood	M-MDSCs were detected as CD45⁺CD11b⁺CD33⁺HLA- DR^lowCD14⁺CD15^–, G-MDSCs (CD33^hi PMN- MDSC) were detected as CD45⁺CD11b⁺CD33^hiHLA- DR^lowCD14^–CD15⁺	10 patients with advanced colorectal carcinoma	Levels of circulating M-MDSCs were not associated with metastatic disease within advanced CRC patients. Levels of circulating CD33^hi PMN-MDSCs were elevated in patients with distant metastases compared to T3 M0 subgroup	[52]
PBMC	M-MDSCs (defined as CD14⁺HLA-DR^–/low) PMN-MDSCs (defined as low density, CD33⁺CD11b⁺CD14^– CD15⁺SSC^hi)	1 CRC patient and 8 healthy donors	A significant expansion of CD38⁺ M-MDSCs and a trend of expansion of CD38⁺ PMN-MDSCs (accompanied by a trend of increased CD38 expression on both M-MDSCs and PMN-MDSCs) were observed in PBMCs of CRC patients when compared with healthy donors	[54]

Return to article view

PBMC: peripheral blood mononuclear cell